Title	Credits	Expiration Date
From Signal Transduction to Epigenetic Regulation of Gene Expression in Oncology: Challenging Challenging Clinical Cases Improving Outcomes for Patients With CML Practical Issues in the Management of CLL Targeting Epigenetics in Cancer Emerging HDACI Combinations in Solid Tumors Roundtable Discussion	1	Nov 20, 2009
Case Studies in Oncology Vol. 9, No. 2 Treatment for Metastatic Pancreatic Cancer	1	Nov 18, 2009
Oncology Briefings Vol. 6, No. 7 Optimizing mTOR and VEGF Inhibitors in Advanced RCC	0.5	Nov 17, 2009
Case Studies in Breast Cancer Vol. 6, No. 7 Bone Health in Hormone Receptor–Negative Early-Stage Breast Cancer	1	Nov 13, 2009
Case Studies in Breast Cancer Vol. 6, No. 6 Adjuvant Therapy for a Patient With HER2⁺ Breast Cancer and Borderline LVEF	1	Nov 12, 2009
Advances in Lung Cancer Vol. 8, No. 1 Targeted Agents in Early-Stage and Locally Advanced NSCLC Safety of Antiangiogenic Agents in Advanced NSCLC Optimizing Chemotherapy in Resectable NSCLC	1	Nov 3, 2009
Refining and Personalizing Treatment for Non–Small-Cell Lung Cancer Current Approaches With EGFR Inhibitors in NCSLC Approaches to Inhibit Angiogenesis: Targeting the Ligand Small-Molecule VEGFR TKIs Class-Effect Toxicities With Antiangiogenic Agents Moving Toward Individualized Cancer Therapy for NSCLC	1	Nov 3, 2009
Case Studies in Oncology Vol. 9, No. 3 GBM: Advances and Challenges	1	Oct 31, 2009
Cancer Summaries & Commentaries Vol. 1, No. 4 Targeted Strategies for Metastatic and Locally Advanced NSCLC	1	Oct 31, 2009
Expanding Options for the Treatment of Metastatic Breast Cancer Novel Inhibitors of HER2 Combination Chemotherapy in MBC First-line Therapy for Aggressive Metastatic Disease Angiogenesis: VEGF- and VEGFR-Targeted Therapies	1	Oct 29, 2009
New Therapeutic Options for Challenging Hematologic Diseases Clinical Value of IPSS Risk Assessment Extending Outcomes in MDS Patient With AML in First Complete Remission Management of a 28-Year-Old Patient With PNH	1	Oct 17, 2009
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 13, No. 2 2008 Oncology Conference Highlights Genomic Profiling Identifies CLL Subtypes MRD Negativity and Consolidation Therapy in CLL	1	Oct 17, 2009
Case Studies in Breast Cancer Vol. 6, No. 5 HER2⁺ Breast Cancer Progressing After Adjuvant Therapy	1	Sep 29, 2009
Case Studies in Pain Management Vol. 2, No. 2 Nociceptive and Neuropathic Pain Management	1	Sep 29, 2009
In-Depth Tumor Board: Biologic Therapy for Breast Cancer Anti-HER2 Therapy for Node-Negative Breast Cancer Cardiotoxicity and Anti-HER2 Therapy Refractory HER2⁺ MBC Antiangiogenic Therapy for MBC Chemotherapy Options for MBC	1	Sep 24, 2009
Case Studies in Oncology Vol. 9, No. 1 Gemcitabine-Refractory Pancreatic Cancer	1	Sep 24, 2009
Case Studies in Breast Cancer Vol. 6, No. 3 Neoadjuvant Treatment of HER2⁺ IBC	1	Sep 12, 2009
Case Studies in Breast Cancer Vol. 6, No. 4 Late-Extended Treatment of Breast Cancer With an AI	1	Sep 12, 2009
Biological Therapy of Breast Cancer Vol. 9, No. 1 Antiangiogenic Agents in Breast Cancer Combining Targeted Agents in Breast Cancer Molecular Aberrations in Breast Cancer and Future Therapy	1	Sep 12, 2009
Oncology Briefings Vol. 6, No. 5 Optimizing the Chemotherapy Backbone in Metastatic NSCLC	0.5	Sep 2, 2009
Receptor-Based Therapeutics: An Interactive Exposé Personalized Cancer Therapy Options for ErbB2-Positive MBC That Has Progressed on ErbB2-Targeted MoAb Therapy Antiangiogenic Therapy in Newly Diagnosed MBC	1	Aug 27, 2009
Cancer Summaries & Commentaries Vol. 1, No. 2 Broadening the Horizon of Targeted Agents in Advanced Non–Small-Cell Lung Cancer Safety of Bevacizumab in Advanced NSCLC With Treated or Untreated CNS Metastases Pemetrexed/Carboplatin Plus Bevacizumab in Advanced Nonsquamous NSCLC Paclitaxel/Carboplatin With or Without CP-751871 as First-line Therapy for Advanced NSCLC rhApo2L/TRAIL Plus Paclitaxel/Cisplatin/Bevacizumab in Advanced Nonsquamous NSCLC XL647 in Patients With NSCLC and Acquired Resistance to Gefitinib or Erlotinib	1	Aug 26, 2009
The Next Generation of Combinations for Breast Cancer: Building on Targeted Therapies Online Only Cancer Summaries & Commentaries Dual HER1/HER2 Inhibition in Refractory MBC Every-3-Week Trastuzumab-MCC-DM1 in HER2⁺ MBC Everolimus/Paclitaxel/Trastuzumab in Trastuzumab-Resistant HER2⁺ MBC Neoadjuvant Letrozole/Everolimus in ER⁺ Breast Cancer Vorinostat/Tamoxifen in AI-Resistant ER⁺ MBC	1	Aug 22, 2009
Case Studies in Breast Cancer Vol. 6, No. 2 First-line Treatment of HER2^– MBC	1	Aug 20, 2009
Cancer Summaries and Commentaries Vol. 1, No. 1 Bevacizumab/Docetaxel in Advanced Breast Cancer Lapatinib With or Without Pazopanib in HER2-Positive MBC Trastuzumab/Pertuzumab for MBC That Had Progressed on Prior Trastuzumab Tanespimycin/Trastuzumab in HER2-Positive MBC That Had Progressed on Prior Trastuzumab Anastrozole/Gefitinib in Postmenopausal Women With Hormone Receptor–Positive MBC Cetuximab With or Without Carboplatin for Triple-Negative MBC	1	Aug 20, 2009
Case Studies in Colorectal Cancer Vol. 4, No. 1 Extended Biologic Treatment of a Patient With Metastatic Colorectal Cancer	1	Jul 15, 2009
The Evolving Paradigm of Molecular-Based Diagnosis and Targeted Therapies in Breast Cancer How Do We Counsel Our Breast Cancer Patients? Diagnostic Testing for Targeted Therapeutics: Lessons Learned From HER2 HER2-Targeted Therapy in the Adjuvant Treatment of Breast Cancer Neoadjuvant Trastuzumab in HER2-Positive Breast Cancer	1	Jun 30, 2009
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 13, No. 1 Chemoimmunotherapy Regimens in Chronic Lymphocytic Leukemia: Recent Updates When and How to Treat Patients With Chronic Lymphocytic Leukemia	1	Jun 27, 2009
Case Studies in Pain Management Vol. 2, No. 1 Treatment of a Patient With Intractable Pain Due to Progressive Pancreatic Cancer	1	Jun 26, 2009
Patient Communication: The Surgeon's Role Interpretation of Breast Cancer Biomarkers Reviewing Individualized Benefits and Side Effects of Systemic Therapy: Decision Tools Communicating the Promises and Limitations of Targeted Therapy The Impact of Advocacy in Cancer Care and Research Learning How to Counsel Our Patients	1	Jun 6, 2009
Oncology Consultations Vol. 5, No. 1 Therapeutic Options for ER⁺/HER2^- Breast Cancer	1	Jun 6, 2009
Case Studies in Ovarian Cancer Vol. 3, No. 1 Clinical Management of a Patient With Platinum-Resistant Ovarian Cancer	1	Jun 6, 2009
From Genome to Clinic: Translating Discoveries Into Practice Targeting Growth Factor Receptors: Current Impact and Future Potential Therapeutic Applications of Angiogenesis-Based Therapies	1	Jun 4, 2009
Molecular Profiling:Improving Precision in Adjuvant Therapy Decisions for Early-Stage Breast Cancer Multigene Assays: A Window Into Breast Cancer Behavior	1	Jun 4, 2009
Rapid Reviews in Oncology: Update in Hematologic Malignancies Frontline Therapies for Multiple Myeloma: A New Landscape Evolving Strategies in the Management of Patients With Chronic Lymphocytic Leukemia Clinical Advances for Patients With Myelodysplastic Syndromes	1	Jun 3, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 3 Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma	1.5	May 28, 2009
Clinical Colorectal Cancer Vol. 7, Suppl. 1 New Developments in Targeted Treatment Strategies for Colorectal Cancer	1.25	May 27, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 1 Novel Agents for Hematologic Malignancies: An Era of Riches	1.25	May 27, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 2 Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma	1	May 27, 2009
Clinical Challenges in Non-Hodgkin Lymphoma: Biologic Strategies for 2008 Improving Outcomes in DLBCL by Altering Current Regimens Biologic Therapy in CLL: Current Data and Ongoing Studies Novel Anti-CD20 Antibodies in NHL Current Trends in Antiangiogenic Therapy in NHL Therapeutic Approaches to Targeting the Apoptotic Pathway in Lymphoma	1	May 15, 2009
Targeted Signal Modulation in Renal Cell Carcinoma and Prostate Cancer The Success of Targeting the Vascular Endothelial Growth Factor Receptor Axis in Renal Cell Carcinoma Small-Molecule VEGFR Inhibitors: Integrating Multiple Lines of Therapy for Recurrent Renal Cell Carcinoma Risk Prognostication and Tumorigenesis in Prostate Cancer Current Approaches to Prevention and Early Intervention in Prostate Cancer	1	May 14, 2009
Case Studies in Lymphoma Vol. 6, No. 2 This activity is intended for medical oncologists and hematologists involved in the care of patients with peripheral T-cell lymphoma. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.	1	May 5, 2009
Case Studies in Breast Cancer Vol. 6, No. 1 ErbB TKIs in ErbB2-Positive IBC	1	May 5, 2009
Breast Cancer Journal Club Vol. 5, No. 2 Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer	1	May 5, 2009
Controversies in Adjuvant Endocrine Therapy for Breast Cancer Adjuvant Endocrine Therapy in 2007: What Have We Accomplished and What Uncertainties Remain? Optimizing Endocrine Therapy for Patients With Newly Diagnosed Early-Stage Breast Cancer Controversies in Adjuvant Endocrine Therapy: Extending Therapy Beyond 5 Years Should All Patients Receiving Adjuvant Aromatase Inhibitors for Breast Cancer Receive Bisphosphonate Support?	1	Apr 25, 2009
Practical Updates in Breast Cancer Adjuvant Chemotherapy for Early-Stage Breast Cancer	2	Apr 15, 2009
Clinical Challenges With Hereditary and Transfusion-Dependent Iron Overload Hereditary Hemochromatosis and Iron Overload Disorders Mechanisms of Action of Iron Chelating Agents Current Perspectives in Measuring LIC Managing Iron Overload in Transfusion-Dependent Patients	1	Apr 4, 2009
Case Studies in Lymphoma Vol. 6, No. 1 Romidepsin in MF and Histologic Large-Cell Transformation	1	Mar 17, 2009
Contemporary Trends in Chemotherapy for Advanced/Metastatic Breast Cancer The Dilemma of Single Versus Combination Therapy: Which Agents and What Clinical Situation? Combinations of Chemotherapy and Biologically Targeted Agents: The Nature of the Synergy and Side-Effect Profile Locally Advanced Breast Cancer as a Model for the Study and Optimization of Chemotherapeutic Regimens The Use of Protein and Genetic Markers in Determining Optimal Chemotherapy: Ready for Prime Time? A Case-Based Debate	1	Mar 10, 2009
Practical Updates in Renal Cell Carcinoma Utilizing Prognosis Assessment for Treatment Strategy Development in Metastatic Renal Cell Carcinoma Case 1: A 65-year-old male Case 2: A 48-year-old female Case 3: A 64-year-old female	1	Mar 3, 2009
Oncology Briefings Vol. 6, No.1 Update on Histone Deacetylase Inhibitors in the Treatment of T-Cell Lymphoma and Multiple Myeloma	0.5	Mar 3, 2009
Oncology Briefings Vol. 6, No. 2 The Bcr-Abl kinase inhibitor imatinib is the current standard of care for the first-line treatment of patients with Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). However, although imatinib yields durable remissions, it is not curative, and some patients have short-lived responses followed by disease progression.	0.5	Mar 3, 2009
Clinical Breast Cancer Vol. 8, Suppl. 1 Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data Management of Febrile Neutropenia and Cardiac Toxicity in the Adjuvant Treatment of Breast Cancer Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors New Strategies for the Treatment of Metastatic Bone Disease	1.5	Mar 3, 2009
Clinical Advances in Breast Cancer Vol. 1, No. 1 HER2-Positive Early-Stage Breast Cancer: Decision-Making and Practical Management Role of Genomics and Emerging Novel Molecular Diagnostic Tests in the Routine Management of Early-Stage Breast Cancer	1	Mar 3, 2009
Oncology Consultations Vol. 4, No. 12 Treatment of HER2-Positive/Hormone Receptor Positive Metastatic Breast Cancer With Endocrine Therapy Plus HER2-Targeted Therapy	1	Mar 3, 2009
Targeted Therapies in Oncology The Extrinsic Pathway: Targeting Death Receptors in Cancer Therapy Targeting the Cell Cycle and DNA Repair Machinery for Cancer Therapy	1	Mar 3, 2009
Oncology Briefings Vol. 5, No. 4 Current and Novel Treatment Strategies for Newly Diagnosed Multiple Myeloma	0.5	Feb 15, 2009
Clinical Colorectal Cancer Vol. 6, Suppl. 2 First-Line Use of Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer James J. Lee, Edward Chu The Role of Epidermal Growth Factor Receptor–Targeted Antibody Therapy in Previously Treated Colorectal Cancer David Watkins, David Cunningham Combining Targeted Therapies to Enhance the Effectiveness of Chemotherapy in Patients with Treatment-Refractory Colorectal Cancer Cathy Eng Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer Eric Van Custem	1.5	Jan 31, 2009
Oncology Consultations Vol. 4, No. 13 Multidisciplinary Management in Patients Presenting With Resectable or Borderline-Resectable Stage IV Colorectal Cancer	1	Jan 17, 2009
Angiogenesis in Oncology Vol. 2, No. 6 Current Status of Antiangiogenesis Therapy of Colorectal Cancer: Timing and Duration of Therapy Combined Modality Therapy in Early-Stage Non-Small-Cell Lung Cancer: The Potential and Future Role of Antiangiogenic Agents Targeting the Tumor Microenvironment	1	Jan 17, 2009
Advances in Lung Cancer Vol. 7, No. 4 Newly Diagnosed, Advanced-Stage Non–Small-Cell Lung Cancer: Considerations for First-line Treatment Second- and Third-line Treatment Options for Advanced Non–Small-Cell Lung Cancer Agents Targeting Mammalian Target of Rapamycin and Heat Shock Protein 90 in Non-Small-Cell Lung Cancer	1	Jan 17, 2009
Case Studies in Breast Cancer Vol.5 No.10 This activity is intended for medical oncologists involved in the care of patients with breast cancer. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity.	1	Dec 26, 2008
Advances in Colon Cancer Vol. 8, No. 2 Preclinical and Early Clinical Data on TRAIL in Colon Cancer The Pathogenesis of Colon Cancer: Role of the Extrinsic (Death Receptor) Pathway of Apoptosis	1	Dec 22, 2008
Oncology Consultations Vol. 4, No. 10 Q&A: Impact of Patient and Tumor Characteristics in Lung Adenocarcinoma SB 1: Second-Line Therapy for Advanced NSCLC SB 2: Impact of Smoking History on Therapy With EGFR TKIs in Lung Cancer	1	Dec 22, 2008
Oncology Consultations Vol. 4, No. 11 Combination Biologic Therapy and Chemotherapy for Metastatic CRC Dual Biologics in Advanced CRC: CALGB/SWOG 80405 Trial Final Results of the BOND-2 Trial Chemotherapy-Associated Liver Toxicity	1	Dec 22, 2008
Emerging Biologic Approaches for the Treatment of Breast Cancer Who Needs Adjuvant HER2-Targeted Therapy? Novel Therapies for HER2-Positive Breast Cancer Confusion on the HER2 Front: Not All Decisions Are Black and White Inhibiting the Tumor Microenvironment Targeting Oncogene Addiction in Breast Cancer: Key Pathways and Novel Targets	1	Dec 22, 2008
Monographs in Hepatocellular Carcinoma Vol. 1, No. 1 Current Perspectives: Etiology and Molecular Pathogenesis of Hepatocellular Carcinoma Targeted Therapy for Hepatocellular Carcinoma: Overview of Current and Future Trials Treatment Approaches for Localized Hepatocellular Carcinoma	1	Dec 14, 2008
Biological Therapy of Breast Cancer Vol. 8, No. 4 Rationale and Clinical Data for Combined Inhibition of HER2 and Vascular Endothelial Growth Factor Receptor Pathways in Breast Cancer Genomic Rearrangements in Breast Cancer: Clinical Implications Putative Breast Cancer Stem Cells as Therapeutic Targets	1	Dec 14, 2008
Controversies in Biologic Therapy of Breast Cancer Controversies in Adjuvant Therapy: Treatment Options for Patients With Node-Negative, HER2-Positive, Early-Stage Breast Cancer Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Positive Disease Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Negative Disease	1	Dec 14, 2008
Cancer Abstracts & Summaries Vol. 8, No. 8 Targeted Agents in NSCLC: Novel Agents, Novel Settings Phase III Trial of First-line Gemcitabine/Cisplatin/Bevacizucmab in Advanced Nonsquamos NSCLC Phase III Trial of Gefitinib Compared to Docetaxel in Patients With Previously Treated Advanced NSCLC Phase II Trial of First-line Erlotinib in Patients With Advanced or Metastatic NSCLC Phase II Trial of First-line XL647 in Patients With NSCLC Enriched for Sensitivity to EGFR Tyrosine Kinase Inhibitors Ongoing Phase II/III Trials of Antiangiogenic Agents in NSCLC	1	Dec 7, 2008
Rapid Reviews in Oncology: Practical Updates on the Management of Multiple Myeloma Introduction and Overview Expert Interviews: A Conversation on Practical Updates in the Management of Multiple Myeloma With Dr. Asher Chanan-Khan and Dr. Sagar Lonial Integration of Anthracyclines Into the Management of Patients With Relapsed/Refractory Multiple Myeloma Advances in Treatment Options for Patients With Newly Diagnosed Multiple Myeloma	1	Dec 7, 2008
Angiogenesis in Oncology Vol. 2, No. 5 Incorporating Antiangiogenic Agents Into the Perioperative Setting for Colorectal Cancer Biology and Management of Hypertension and Other Class-Effect Toxicities Related to Antiangiogenic Therapy Novel Avenues in Antivascular Tumor Therapy	1	Dec 7, 2008
Targeted Therapies and Evolving Treatment Paradigms for Lung Cancer Molecular Pathogenesis of NSCLC Individualizing Therapies in NSCLC Based on Tumor Biology and Patient Characteristics Optimizing the Use of EGFR Inhibitors in Patients With NSCLC Integration of Antiangiogenesis Agents Into Treatment Paradigms for NSCLC Quality of Life and Adverse Events Associated With targeted Therapy in NSCLC New Therapeutic Agents for NSCLC	1	Dec 7, 2008
Targeted Therapies in Oncology Vol. 6, No. 1 Novel Strategies for Treating Ovarian Cancer Emerging Monoclonal Antibodies for the Treatment of HER2-Positive Breast Cancer	1	Dec 7, 2008
Current Perspectives on Targeted Therapies for Advanced Renal Cell Carcinoma Neoadjuvant Targeted Therapy Approaches in Advanced RCC Targeted Therapies as Standard of Care in mRCC Are Multitargeted TKIs the Standard of Care in Patients With Previously Treated mRCC? Sequential Targeted Therapy in RCC	1	Nov 30, 2008
Optimal Application of Epidermal Growth Factor Receptor and Angiogenesis Inhibitors in Lung Cancer Targeting Angiogenesis in Non-Small-Cell Lung Cancer Novel High-Affinity Vascular Endothelial GrowthFactor/Multitargeted Tyrosine Kinase Inhibitors Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non—Small-Cell Lung Cancer: Where Are We in 2007? Overcoming Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors	1	Nov 30, 2008
Beyond Taxanes: New Chemotherapeutic Options for Patients With Refractory Metastatic Breast Cancer Multidrug Resistance and Microtubule-Inhibiting Agents: Underlying Mechanisms and Predictive Factors Epothilones and Other Novel Microtubule-Targeting Agents in Clinical Development Practical Management of Resistant/Refractory Metastatic Breast Cancer	1	Nov 30, 2008
Cancer Conference Highlights Vol. 9, No. 9 Current and Future Therapeutic Options for Patients With Advanced Hormone-Refractory Prostate Cancer Novel Oral Platinum Analogues in the Treatment of Patients With Hormone-Refractory Prostate Cancer Satraplatin in Hormone-Refractory Prostate Cancer Molecular-Targeted Agents in Advanced Prostate Cancer Targeting Epigenetics in Prostate Cancer	1	Nov 30, 2008
Utilizing Genomic Tools for Decision Making in Hormone Receptor-Positive Early-Stage Breast Cancer Genomic Tools for Decision Making in Early-Stage Breast Cancer	1	Nov 30, 2008
Advances in Lung Cancer Vol. 7, No. 3 Response to TKIs Targeting EGFR Second-Generation EGFR TKIs	1	Nov 20, 2008
Translating the Complexities of Cancer Development Into Novel Therapeutics Summaries of Lectures From a Satellite Symposium Held in Conjunction With the 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1-5, 2007	1	Nov 20, 2008
Oncology Briefings Vol.5, No.8 Novel Paclitaxel Formulations	0.5	Nov 20, 2008
New Paradigms in the Biologic Therapy of Breast Cancer: Translating Advances in Molecular Biology Into Improved Patient Outcomes Individualization of HER2-Targeted Therapy in Early-Stage Breast Cancer Novel Approaches to HER2-Positive Breast Cancer: Emerging Targeting Agents Practical Considerations for Angiogenesis Inhibition in Advanced Breast Cancer Multiplying the Benefits: Novel Combinations of Targeted Agents Contributions of c-Myc Amplification and Other Genetic Alterations in HER2-Positive Breast Cancer	1	Nov 20, 2008
Oncology Consultations Vol. 4, No. 9 Treatment of a Premenopausal Patient With HR-Positive/Node-Negative Breast Cancer With Adjuvant Therapy	1	Nov 20, 2008
Emerging Pathways With Therapeutic Potential in Cancer Targeting Signaling Pathways to Inhibit Cancer Growth Targeting the MAP/MEK and PI3K/Akt Pathways Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer Vaccines in Lung Cancer Novel Immunologic Targets in Metastatic Melanoma Combining Targeted Agents to Improve Therapeutic Efficacy	1	Nov 20, 2008
Controversies in Management of Non-Hodgkin Lymphoma Debate 1: The 2007 Standard of Care for Aggressive Lymphomas Should Be R-CHOP Every Two Weeks Debate 2: All Patients With Follicular Lymphoma Should Receive Maintenance Rituximab Debate 3: Rituximab Plus Chemotherapy Followed by Autologous Stem Cell Transplantation Consolidation Is the Optimal Therapy for Mantle Cell Lymphoma	1	Nov 20, 2008
Novel Cytotoxic and Targeted Agents in Lymphoproliferative Disorders Bifunctional Alkylators Plus Other Cytotoxic Agents in Lymphomas Incorporating Proteasome Inhibitors Into Treatment of MCL Novel Approaches to CLL: MoAbs Plus Novel Cytotoxic Agents The Role of Novel Antibodies in Hematologic Malignancies	1	Nov 20, 2008
The Evolving Utility of Biologic Therapy in Breast Cancer Optimizing Adjuvant Therapy With HER2-Targeted MoAbs Clinical Utility and Future Prospects of Small-Molecule HER TKIs Breast Cancer Resistant to HER2-Targeted Therapies Clinical Utility and the Future of Angiogenesis Inhibitor Therapy Emerging Applications of IGF-1R–Targeted Therapy	1	Nov 20, 2008

Highlighted Publications

Practical Updates in Renal Cell Carcinoma

Expiration Date: Mar 3, 2009

Angiogenesis in Oncology Vol. 2, No. 6

Expiration Date: Jan 17, 2009

Publications

Browse Publications By...

Search All Publications

Highlighted Publications

What's New

Contact PER